Bridgebio Pharma Inc (BBIO) Directors and Executive Officers

Brian Stephenson
Chief Financial Officer - (Principal Financial Officer and Principal Accounting Officer)

Jennifer E. Cook
Director -

Randal W. Scott
Director -

Ronald J. Daniels
Director -

Charles Homcy
Director -

Frank P. McCormick
Director -

Hannah A. Valantine
Director -

Eric Aguiar
Director -

Andrea J. Ellis
Director -

Fred Hassan
Director -

Neil Kumar
President, Chief Executive Officer and Director - (Principal Executive Officer)

Ali J. Satvat
Director -

Douglas A. Dachille
Director -

Andrew W. Lo
Director -

James C. Momtazee
Director - ,

Bridgebio Pharma Inc currently has 839 employees.

News about Bridgebio Pharma Inc Key Personnel

BridgeBio Pharma Faces Tumultuous Path: High Hopes and Deep Losses in Genetic Disease Treatments

BridgeBio Pharma: Navigating the Dichotomy of Rising Demand and Pertinent Financial LossesIn the realm of biotechnology, where innovation is as commendable as it is hazardous, BridgeBio Pharma Inc. stands at a crossroads. The Palo Alto-based company has recently reported remarkable strides in its portfolio, particularly concerning treatments for genetic diseases such as transthyretin amyloid cardiomyopathy (ATTR-CM) and achondroplasia. However, amidst this commercial progress, the company grapples with staggering financial losses that raise questions about its long-term viability.BridgeBio announced a cumulative net loss of $446 million for the 12 months ending the third quarter of 2024. This dismal figure...

BridgeBio Pharma: Striving for Growth through Inducement Grants and Stock Potential in Genetic Disease & Cancer Pursuit

In a recent press release, BridgeBio Pharma, a prominent biopharmaceutical company specializing in genetic diseases and cancers, announced the approval of equity grants for 24 new employees. These grants, in the form of restricted stock units, amount to a total of 97,557 shares of the company s common stock. Notably, the vesting of these shares will be staggered over time, contingent upon the employees continued employment with the company. These inducement grants were made in accordance with BridgeBio s Amended and Restated 2019 Inducement Equity Plan (the Plan).
This development follows BridgeBio Pharma s financial performance for the twelve months ending in the third quarter of 2023. During this...

BridgeBio Unveils $200M Financing to Fast-Track Precision Oncology Pipeline

BridgeBio Accelerates Oncology Pipeline with $200M Financing
BridgeBio Pharma, a leading biopharmaceutical company focused on genetic diseases and cancers, has announced the completion of a $200M private financing for its subsidiary, BridgeBio Oncology Therapeutics (BBOT). This strategic move aims to expedite the development of BridgeBio s precision oncology pipeline and further advance its mission to deliver innovative treatments for cancer patients.
The oversubscribed financing round was led by Cormorant Asset Management and co-led by Omega Funds, with participation from renowned investors including Deerfield Management, GV (Google Ventures), EcoR1 Capital, and Wellington Management, among others. ...

BridgeBio Pharma Furthers Genetic Disease & Cancer Pursuit with Inducement Grants, Continues to Improve ROA Ranking

BridgeBio Pharma's Strategic Offering Sets the Stage for Genetic Disease and Cancer Breakthroughs

BridgeBio Pharma Announces Pricing of Public Offering of Common Stock - A Strategic Move to Boost Genetic Disease and Cancer Research
PALO ALTO, Calif., March 5, 2024 - BridgeBio Pharma, Inc. (Nasdaq: BBIO), a leading commercial-stage biopharmaceutical company dedicated to genetic diseases and cancers, has recently announced the pricing details of a public offering of its common stock. This underwritten public offering consists of 8,620,690 shares at a price of $29.00 per share. BridgeBio has also granted the underwriters an option to purchase an additional 1,293,103 shares on the same terms. With an expected gross proceeds of approximately $250.0 million, this move is aimed at supporting their ongoing ...